{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:49Z","timestamp":1776408709760,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06925-1","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:42:28Z","timestamp":1772862148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and prognostic features of patients with blastoid and pleomorphic variant mantle cell lymphoma: a real-world study in China"],"prefix":"10.1007","volume":"105","author":[{"given":"Ying","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"6925_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M (2019) Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94:710\u2013725. https:\/\/doi.org\/10.1002\/ajh.25487","journal-title":"Am J Hematol"},{"key":"6925_CR2","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102:83\u201387","journal-title":"Pathologica"},{"key":"6925_CR3","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3109\/10428194.2015.1026902","volume":"56","author":"R Shrestha","year":"2015","unstructured":"Shrestha R, Bhatt VR, Guru Murthy GS, Armitage JO (2015) Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk Lymphoma 56:2759\u20132767. https:\/\/doi.org\/10.3109\/10428194.2015.1026902","journal-title":"Leuk Lymphoma"},{"key":"6925_CR4","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1182\/bloodadvances.2023010757","volume":"7","author":"JN Gerson","year":"2023","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S et al (2023) Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv 7:7393\u20137401. https:\/\/doi.org\/10.1182\/bloodadvances.2023010757","journal-title":"Blood Adv"},{"key":"6925_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1309\/te56-a43x-29tt-5h8g","volume":"118","author":"Z Liu","year":"2002","unstructured":"Liu Z, Dong HY, Gorczyca W, Tsang P, Cohen P, Stephenson CF et al (2002) CD5- mantle cell lymphoma. Am J Clin Pathol 118:216\u2013224. https:\/\/doi.org\/10.1309\/te56-a43x-29tt-5h8g","journal-title":"Am J Clin Pathol"},{"key":"6925_CR6","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","volume":"132","author":"M Dreyling","year":"2018","unstructured":"Dreyling M, Klapper W, Rule S (2018) Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 132:2722\u20132729. https:\/\/doi.org\/10.1182\/blood-2017-08-737502","journal-title":"Blood"},{"key":"6925_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"6925_CR8","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","volume":"6","author":"M Narkhede","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S (2022) Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 6:4122\u20134131. https:\/\/doi.org\/10.1182\/bloodadvances.2022007247","journal-title":"Blood Adv"},{"key":"6925_CR9","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH et al (2023) Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis. Cancer Med 12:13204\u201313216. https:\/\/doi.org\/10.1002\/cam4.6009","journal-title":"Cancer Med"},{"key":"6925_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/jco.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S et al (2019) Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol 37:471\u2013480. https:\/\/doi.org\/10.1200\/jco.18.00690","journal-title":"J Clin Oncol"},{"key":"6925_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdv074","volume":"26","author":"D Chihara","year":"2015","unstructured":"Chihara D, Asano N, Ohmachi K, Nishikori M, Okamoto M, Sawa M et al (2015) Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol 26:966\u2013973. https:\/\/doi.org\/10.1093\/annonc\/mdv074","journal-title":"Ann Oncol"},{"key":"6925_CR12","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B et al (2012) Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963\u20131971. https:\/\/doi.org\/10.1182\/blood-2011-11-391474","journal-title":"Blood"},{"key":"6925_CR13","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Be\u00e0","year":"2013","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P et al (2013) Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110:18250\u201318255. https:\/\/doi.org\/10.1073\/pnas.1314608110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6925_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/pas.0000000000002068","volume":"47","author":"M Khanlari","year":"2023","unstructured":"Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P et al (2023) Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol 47:849\u2013858. https:\/\/doi.org\/10.1097\/pas.0000000000002068","journal-title":"Am J Surg Pathol"},{"key":"6925_CR15","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00277-023-05597-5","volume":"103","author":"P Yang","year":"2024","unstructured":"Yang P, Liu SZ, Li CY, Zhang WL, Wang J, Chen YT et al (2024) Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China. Ann Hematol 103:2381\u20132391. https:\/\/doi.org\/10.1007\/s00277-023-05597-5","journal-title":"Ann Hematol"},{"key":"6925_CR16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","volume":"4","author":"P Jain","year":"2020","unstructured":"Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN et al (2020) Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4:1038\u20131050. https:\/\/doi.org\/10.1182\/bloodadvances.2019001396","journal-title":"Blood Adv"},{"key":"6925_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J et al (2016) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17:48\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(15)00438-6","journal-title":"Lancet Oncol"},{"key":"6925_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.15411","volume":"182","author":"P Jain","year":"2018","unstructured":"Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J et al (2018) Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL). Br J Haematol 182:404\u2013411. https:\/\/doi.org\/10.1111\/bjh.15411","journal-title":"Br J Haematol"},{"key":"6925_CR19","doi-asserted-by":"publisher","unstructured":"Burkart M, Karmali R (2022) Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. J Pers Med 12. https:\/\/doi.org\/10.3390\/jpm12030376","DOI":"10.3390\/jpm12030376"},{"key":"6925_CR20","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1002\/cam4.4765","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu P, Cai J, Jing H, Zou L, Huang H et al (2022) Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed\/refractory mantle cell lymphoma: A multicenter study. Cancer Med 11:4134\u20134145. https:\/\/doi.org\/10.1002\/cam4.4765","journal-title":"Cancer Med"},{"key":"6925_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L et al (2022) Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u2264\u200965 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23:406\u2013415. https:\/\/doi.org\/10.1016\/s1470-2045(21)00638-0","journal-title":"Lancet Oncol"},{"key":"6925_CR22","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD et al (2019) Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33:2762\u20132766. https:\/\/doi.org\/10.1038\/s41375-019-0575-9","journal-title":"Leukemia"},{"key":"6925_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1200\/jco.21.02698","volume":"41","author":"P Martin","year":"2023","unstructured":"Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D et al (2023) Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol 41:541\u2013554. https:\/\/doi.org\/10.1200\/jco.21.02698","journal-title":"J Clin Oncol"},{"key":"6925_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/jco.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M et al (2020) Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 38:248\u2013256. https:\/\/doi.org\/10.1200\/jco.19.01294","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06925-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:47Z","timestamp":1776405587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06925-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6925"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06925-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the clinical research ethics committee of the first affiliated hospital, college of medicine, Zhejiang University. The informed consent was waived because this study was a retrospective study with review of related data through the electronic medical record.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}